Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Research & Development: 2010-2018

Historic Research & Development for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to $6.2 million.

  • EyePoint Pharmaceuticals' Research & Development rose 63.21% to $6.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $18.6 million, marking a year-over-year increase of 28.04%. This contributed to the annual value of $16.2 million for FY2018, which is 8.72% up from last year.
  • As of Q3 2018, EyePoint Pharmaceuticals' Research & Development stood at $6.2 million, which was up 30.81% from $4.8 million recorded in Q2 2018.
  • In the past 5 years, EyePoint Pharmaceuticals' Research & Development ranged from a high of $6.2 million in Q3 2018 and a low of $2.3 million during Q1 2014.
  • Over the past 3 years, EyePoint Pharmaceuticals' median Research & Development value was $4.1 million (recorded in 2016), while the average stood at $4.0 million.
  • In the last 5 years, EyePoint Pharmaceuticals' Research & Development fell by 14.94% in 2016 and then skyrocketed by 63.21% in 2018.
  • Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' Research & Development stood at $2.8 million in 2014, then surged by 34.48% to $3.7 million in 2015, then fell by 14.94% to $3.2 million in 2016, then surged by 34.88% to $4.3 million in 2017, then spiked by 63.21% to $6.2 million in 2018.
  • Its last three reported values are $6.2 million in Q3 2018, $4.8 million for Q2 2018, and $3.3 million during Q1 2018.